RxDoctor Payments Data

Lauren Murrill, MD

Otolaryngology · Southfield, MINPI 1366708554

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.3% of the total across 137 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations.

$5,074in general payments, 2019–2025

Across 137 payments — averaging $37.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Stryker$891
  • GSK$672
  • Intersect ENT, Inc.$662
  • Regeneron Healthcare Solutions, Inc.$447
  • Sanofi$416
  • plus $899 from 14 others

What the payments were for

  • Food & beverage$5,04099%
  • Education$341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,074 in reported general payments places this provider in the 80th percentile of 257 otolaryngology providers in Michigan.

See all otolaryngology providers in Michigan

Medicare billing

Part B allowed, 2024
$133,170
Medicare patients
453
Services billed
1,826

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Epinephrine38$6,995
Ipratropium Bromide218$5,906
Azelastine Hcl187$4,890
Famotidine342$3,518
Fluticasone Propionate121$1,683
Prednisolone Acetate18$1,003
Ofloxacin47$929
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip52$810
Nystatin20$444
Mupirocin55$354
Omeprazole15$304
Pantoprazole Sodium20$227
Doxycycline Monohydrate28$226
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav22$224
Montelukast Sodium20$138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USAEpinephrine$16$6,99538 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 257 otolaryngology providers in Michigan.

Other otolaryngology in Southfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →